Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 4/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167686 | 0.88 | LTA4H (0.56) | HDAC1LTA4HCHRM4CNR2JAK2 | |
| SCHEMBL5167382 | 0.85 | HDAC1 (0.48) | HDAC1LTA4HGRM2CHRM4CNR2 | |
| SCHEMBL5165935 | 0.83 | HDAC1 (0.63) | HDAC1LTA4HCHRM4JAK2CYP2D6 | |
| SCHEMBL1911332 | 0.80 | LTA4H (0.60) | HDAC1LTA4HCHRM4CYP2D6DRD2 | |
| SCHEMBL13024536 | 0.80 | LTA4H (0.60) | HDAC1LTA4HCHRM4CYP2D6DRD2 | |
| SCHEMBL13634431 | 0.80 | LTA4H (0.60) | HDAC1LTA4HCHRM4CYP2D6DRD2 | |
| SCHEMBL5169012 | 0.79 | LTA4H (0.50) | HDAC1LTA4HGRM2CHRM4CNR2 | |
| SCHEMBL5167418 | 0.78 | NPC1 (0.59) | HDAC1LTA4HALDH1A1LMNATP53 | |
| SCHEMBL5170114 | 0.77 | HDAC1 (0.53) | HDAC1LTA4HGRM2CHRM4JAK2 | |
| SCHEMBL5166411 | 0.76 | GRM2 (0.56) | HDAC1LTA4HGRM2CHRM4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | claimed |
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | HRH3, HRH4, HRH2 | HDAC1 1532/4885LTA4H 395/4885GRM2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.